Drug Search Results
More Filters [+]

AN-2718

Alternative Names: an-2718, an2718, an 2718
Latest Update: 2008-11-21
Latest Update Note: Clinical Trial Update

Product Description

Pfizer was developing an-2718, a topical LeuRS inhibitor, for the treatment of tinea pedis (Sourced from: https://clinicaltrials.gov/ct2/show/NCT00781664)

Mechanisms of Action: LeuRS Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Topical

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for AN-2718

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Tinea Pedis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

AN2718-TP-101

P1

Completed

Tinea Pedis

2008-11-01

22%

Recent News Events

Date

Type

Title